Annual ROA
-131.17%
-58.77%-81.17%
December 31, 2023
Summary
- As of February 7, 2025, IKT annual return on assets is -131.17%, with the most recent change of -58.77% (-81.17%) on December 31, 2023.
- During the last 3 years, IKT annual ROA has fallen by -92.74% (-241.32%).
- IKT annual ROA is now -276.71% below its all-time high of -34.82%, reached on December 31, 2021.
Performance
IKT ROA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROA
-201.82%
-61.18%-43.50%
September 30, 2024
Summary
- As of February 7, 2025, IKT quarterly return on assets is -201.82%, with the most recent change of -61.18% (-43.50%) on September 30, 2024.
- Over the past year, IKT quarterly ROA has dropped by -61.18% (-43.50%).
- IKT quarterly ROA is now -428.74% below its all-time high of -38.17%, reached on March 31, 2022.
Performance
IKT Quarterly ROA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROA Formula
ROA = Net Income
Total Assets ✕ 100%
Total Assets ✕ 100%
IKT ROA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -81.2% | -43.5% |
| 3 y3 years | -241.3% | -226.2% |
| 5 y5 years | -73.5% | -226.2% |
IKT ROA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -276.7% | at low | -428.7% | at low |
| 5 y | 5-year | -276.7% | +66.9% | -428.7% | +98.7% |
| alltime | all time | -276.7% | +66.9% | -428.7% | +98.7% |
Inhibikase Therapeutics ROA History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -201.82%(+43.5%) |
| Jun 2024 | - | -140.64%(+20.5%) |
| Mar 2024 | - | -116.72%(+27.1%) |
| Dec 2023 | -131.17%(+81.2%) | -91.82%(+12.0%) |
| Sep 2023 | - | -81.99%(+12.1%) |
| Jun 2023 | - | -73.17%(+18.3%) |
| Mar 2023 | - | -61.87%(+7.9%) |
| Dec 2022 | -72.40% | -57.36%(+9.3%) |
| Sep 2022 | - | -52.48%(+12.2%) |
| Jun 2022 | - | -46.77%(+22.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | -38.17%(-3.6%) |
| Dec 2021 | -34.82%(-9.4%) | -39.58%(-11.0%) |
| Sep 2021 | - | -44.45%(-3.4%) |
| Jun 2021 | - | -46.02%(-46.8%) |
| Mar 2021 | - | -86.55%(+1.4%) |
| Dec 2020 | -38.43%(-90.3%) | -85.32%(-80.4%) |
| Sep 2020 | - | -434.23%(-75.5%) |
| Jun 2020 | - | -1770.47%(-85.2%) |
| Mar 2020 | - | -11.93 K%(-20.1%) |
| Dec 2019 | -396.78%(+424.7%) | -14.94 K% |
| Dec 2018 | -75.62% | - |
FAQ
- What is Inhibikase Therapeutics annual return on assets?
- What is the all time high annual ROA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual ROA year-on-year change?
- What is Inhibikase Therapeutics quarterly return on assets?
- What is the all time high quarterly ROA for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly ROA year-on-year change?
What is Inhibikase Therapeutics annual return on assets?
The current annual ROA of IKT is -131.17%
What is the all time high annual ROA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual return on assets is -34.82%
What is Inhibikase Therapeutics annual ROA year-on-year change?
Over the past year, IKT annual return on assets has changed by -58.77% (-81.17%)
What is Inhibikase Therapeutics quarterly return on assets?
The current quarterly ROA of IKT is -201.82%
What is the all time high quarterly ROA for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly return on assets is -38.17%
What is Inhibikase Therapeutics quarterly ROA year-on-year change?
Over the past year, IKT quarterly return on assets has changed by -61.18% (-43.50%)